NCT07112872
A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
At risk: Primary completion moved at least 1 year 2 months later, primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 16 versions: 16 with changes below. See every version on ClinicalTrials.gov ↗
Notable Enrollment reopened Show 5 more changesShow less
- Primary endpoint(s) modified
- Trial sites expanded: 46 → 51 locations
- Interventions modified
- Secondary endpoints revised (9)
- Study title expanded, about 1 word
Notable Primary and study completion pushed from Nov 27, 2026 to Feb 5, 2028 Show 6 more changesShow less
- Eligibility criteria expanded, about 14 words
- Enrollment increased: 240 → 330 participants
- Trial sites reduced: 50 → 46 locations
- Trial arms changed: 9 → 12
- Secondary endpoints revised (9)
- Study title shortened, about 1 word
- Minor Study sites revised (50)v14
- Minor Trial status changed: Recruiting → Active, Not Recruiting
- Primary and study completion moved earlier from Feb 8, 2027 to Nov 27, 2026
- Study sites: 51 to 50
- Minor Study sites revised (51)v12
Show 10 earlier versionsHide 10 earlier versions
- Minor Study sites revised (51)v11
- Minor Study sites: 49 to 51v10
- Minor Study sites: 46 to 49v9
- Minor Study sites: 37 to 46v8
- Minor Study sites: 30 to 37v7
- Minor Study sites: 22 to 30v6
- Minor Study sites: 17 to 22v5
- Minor Study sites: 9 to 17
- Start date changed from estimate of Aug 31, 2025 to Aug 19, 2025
- Minor Study sites: 6 to 9
- Secondary endpoints revised (9)
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 6
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Tifeglipron vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30
Timeframe: Baseline to Week 30
Secondary (9)
Tifeglipron vs. Semaglutide (Part A): Change in HbA1c from Baseline at Week 30
Percentage of Participants with HbA1c <5.7%, ≤6.5%, and <7.0% at Week 30
Change in Fasting Plasma Glucose from Baseline at Week 30
Percent Change in Body Weight from Baseline at Week 30
Absolute Change in Body Weight (kg) from Baseline at Week 30
Show 4 moreShow less
Percentage of Participants Who Achieve ≥5%, ≥10%, or ≥15% Body Weight Reduction from Baseline at Week 30
Incidence of Adverse Events (AEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs)
Number of Participants with Documented Hypoglycemia (Level 1, 2, or 3 per American Diabetes Association 2025)
Plasma Concentrations of Tifeglipron at Prespecified Timepoints
Arms and interventions
Part A, Arm 1: PlaceboPlacebo comparator
Part A, Arm 2: Semaglutide 14 mgActive comparator
Part A, Arm 3: Tifeglipron Dosing Regimen 1Experimental
Part A, Arm 4: Tifeglipron Dosing Regimen 2Experimental
Part A, Arm 5: Tifeglipron Dosing Regimen 3Experimental
Part A, Arm 6: Tifeglipron Dosing Regimen 4Experimental
Part A, Arm 7: Tifeglipron Dosing Regimen 5Experimental
Part A, Arm 8: Tifeglipron Dosing Regimen 6Experimental
Part A, Arm 9: Tifeglipron Dosing Regimen 7Experimental
Part B, Arm 1: PlaceboPlacebo comparator
Part B, Arm 2: Tifeglipron Dosing Regimen AExperimental
Part B, Arm 3: Tifeglipron Dosing Regimen BExperimental
Drugs: Tifeglipron, Semaglutide, Placebo
Sites
51 sites in 4 countries
United States 24, Spain 15, Poland 10, Hungary 2